Skip to search formSkip to main contentSkip to account menu

pertuzumab Injection [Perjeta]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

14 ML pertuzumab 30 MG/ML Injection [Perjeta]
InjectionPerjeta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract P1-18-14: Use of pertuzumab in combination with taxanes for HER2+ metastatic breast cancer: Analysis of U.S. electronic health records
Background: Clinical practice guidelines recommend the combination of pertuzumab (PERJETA®), trastuzumab (Herceptin®) (PH) and a… 
Review
2017
Review
2017
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the… 
2016
2016
Pertuzumab in HER2-positive breast cancer: a guide to its use
Pertuzumab (Perjeta®) is a humanized anti-HER2 monoclonal antibody that reduces the proliferation and survival of HER2-positive… 
2013
2013
Cost Effectiveness of Pertuzumab ( Perjeta ® ) in Combination with Trastuzumab and Docetaxel in Adults with HER 2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
  • 2013
  • Corpus ID: 11362931
The HSE has asked the National Centre for Pharmacoeconomics (NCPE) to evaluate the manufacturers (Roche Products Ltd) economic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)